WCN26-6941 Prednisolone Monotherapy versus Low-Dose Prednisolone and Rituximab Therapy in Primary Focal Segmental Glomerulosclerosis and Minimal Change Disease - A randomised control trial in a tertiary center of Eastern part of India

Read full text Summarise with VIRAT
Authors: Pinaki Mukhopadhyay
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) are the leading primary podocytopathies responsible for adult nephrotic syndrome. Conventional high-dose corticosteroid therapy achieves remission but at the cost of significant metabolic and infectious toxicity. Rituximab, a B-cell–depleting monoclonal antibody, may allow comparable efficacy with reduced steroid burden.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104875–104875
Publication date
25 March 2026
Language
EN